MARK2 and lung adenocarcinoma: BRAF is a serine/threonine kinase, which is mediated by the RAS‐RAF‐MEK‐ERK signaling pathway,1 and BRAF mutations have been previously observed in about 1%–5% of lung adenocarcinomas.2, 9, 10